Stock Track | Belite Bio Plummets 5.94% Intraday After Q4 Earnings Miss and Widening Losses

Stock Track03-02

Belite Bio, Inc. shares plummeted 5.94% during intraday trading on Monday, as the clinical-stage drug developer released its preliminary fourth quarter and full year 2025 financial results.

The company reported a GAAP net loss of $25.3 million for the fourth quarter, significantly wider than the $10.1 million loss reported in the same period last year. On a per-share basis, Belite Bio posted a quarterly loss of $(0.70), which missed the analyst consensus estimate of $(0.54) by 29.15%. For the full year 2025, the company reported a net loss of $77.611 million.

While Belite Bio provided updates on its lead candidate tinlarebant, including positive Phase 3 trial results and plans to submit a New Drug Application to the FDA in the second quarter of 2026, investors focused on the deteriorating financial performance and earnings miss, leading to the sharp sell-off.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1134101126?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-03-02 22:47","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1134101126","market":"sg","top_or_hot":-1,"title":"Stock Track | Belite Bio Plummets 5.94% Intraday After Q4 Earnings Miss and Widening Losses","media":"Stock Track","content":"<p>Belite Bio, Inc. shares plummeted 5.94% during intraday trading on Monday, as the clinical-stage drug developer released its preliminary fourth quarter and full year 2025 financial results.</p><p>The company reported a GAAP net loss of $25.3 million for the fourth quarter, significantly wider than the $10.1 million loss reported in the same period last year. On a per-share basis, Belite Bio posted a quarterly loss of $(0.70), which missed the analyst consensus estimate of $(0.54) by 29.15%. For the full year 2025, the company reported a net loss of $77.611 million.</p><p>While Belite Bio provided updates on its lead candidate tinlarebant, including positive Phase 3 trial results and plans to submit a New Drug Application to the FDA in the second quarter of 2026, investors focused on the deteriorating financial performance and earnings miss, leading to the sharp sell-off.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | Belite Bio Plummets 5.94% Intraday After Q4 Earnings Miss and Widening Losses</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | Belite Bio Plummets 5.94% Intraday After Q4 Earnings Miss and Widening Losses\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2026-03-02 22:47</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Belite Bio, Inc. shares plummeted 5.94% during intraday trading on Monday, as the clinical-stage drug developer released its preliminary fourth quarter and full year 2025 financial results.</p><p>The company reported a GAAP net loss of $25.3 million for the fourth quarter, significantly wider than the $10.1 million loss reported in the same period last year. On a per-share basis, Belite Bio posted a quarterly loss of $(0.70), which missed the analyst consensus estimate of $(0.54) by 29.15%. For the full year 2025, the company reported a net loss of $77.611 million.</p><p>While Belite Bio provided updates on its lead candidate tinlarebant, including positive Phase 3 trial results and plans to submit a New Drug Application to the FDA in the second quarter of 2026, investors focused on the deteriorating financial performance and earnings miss, leading to the sharp sell-off.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BLTE","symbol_name":"Belite Bio, Inc.","start_time":0,"source_url":"","article_id":"1134101126","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1134101126","pubTimestamp":1772462873,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Belite Bio, Inc. shares plummeted 5.94% during intraday trading on Monday, as the clinical-stage drug developer released its preliminary fourth quarter and full year 2025 financial results.The...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BLTE":"Belite Bio, Inc."},"translate_title":"个股追踪|Q4财报未达预期亏损扩大贝利特生物盘中暴跌5.94%","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"BLTE":1},"content_text":"Belite Bio, Inc. shares plummeted 5.94% during intraday trading on Monday, as the clinical-stage drug developer released its preliminary fourth quarter and full year 2025 financial results.The company reported a GAAP net loss of $25.3 million for the fourth quarter, significantly wider than the $10.1 million loss reported in the same period last year. On a per-share basis, Belite Bio posted a quarterly loss of $(0.70), which missed the analyst consensus estimate of $(0.54) by 29.15%. For the full year 2025, the company reported a net loss of $77.611 million.While Belite Bio provided updates on its lead candidate tinlarebant, including positive Phase 3 trial results and plans to submit a New Drug Application to the FDA in the second quarter of 2026, investors focused on the deteriorating financial performance and earnings miss, leading to the sharp sell-off.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-2","news_tag":"movement","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.38.0","shortVersion":"4.38.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1134101126","isCrawlerRequest":true}